Therapy of Untreated Acute Myeloid Leukemia in the Elderly: Remission-Induction Using a Non-Cytarabine-Containing Regimen of Mitoxantrone Plus Etoposide

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1345-1352

  Bow, E J ^a   Sutherland, J A ^b   Kilpatrick, M G ^b   Williams, G J ^b   Clinch, J J ^b   Shore, T B ^b   Rubinger, M ^b   Schacter, B A ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CD34 ANTIGEN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MITOXANTRONE; PREDNISOLONE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGING; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INJURY; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; STOMATITIS; THORAX PAIN; TOPICAL DRUG ADMINISTRATION; VOMITING;

ACUTE DISEASE; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INTESTINAL MUCOSA; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029966676     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1345     Document Type: Article

References (42)

1. Burge PS, Prankerd TA, Richards JPM, et al: Quality and quantity of survival in acute myeloid leukemia. Lancet 2:621-624, 1975
2. Crosby WH: Acute granulocytic leukemia (AGL) in the elderly. Arch Intern Med 136:493-494, 1976 (letter)
3. Stone RM, Mayer RJ: The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 7:65-79, 1993
4. Johnson PRE, Liu Yin JA: Acute myeloid leukemia in the elderly: Biology and treatment. Br J Haematol 83:1-6, 1993
5. Baudard M, Marie JP, Cadiou M, et al: Acute myelogenous leukemia on the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 86:82-91, 1994
6. Dillman RO, Davis RB, Green MR, et al: A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 78:2520-2526, 1991
7. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
8. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
9. Arlin Z, Case DC, Moore J, et al: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183, 1990
10. Liu Yin JA, Johnson PRE, Davies JM, et al: Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 79:415-420, 1991
11. Shepherd JD, Reece DE, Barnett MJ, et al: Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leuk Lymphoma 9:211-215, 1993
12. Bishop JF, Lowenthal RM, Joshua D, et al: Etoposide in acute nonlymphocytic leukemia. Blood 75:27-32, 1990
13. Ho AD, Lipp T, Ehninger G, et al: Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - An active and well tolerated regimen. J Clin Oncol 6:213-217, 1988
14. Knauf WU, Berdel WE, Ho AD, Kreuser E-D, et al: Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 12:421-425, 1994
15. Rowe JM, Andersen JW, Mazza JJ, et al: Treatment of relapsed and refractory AML with mitoxantrone and etoposide: A study of the Eastern Cooperative Oncology Group. Haematol Blood Transfus 35:235-238, 1994
16. Van Echo DA, Shulman PN, Ferrari A, et al: A phase II trial of mitoxantrone (DHAD NSC-301739) in adult acute leukemia. Proc Am Soc Clin Oncol 1:132, 1982 (abstr)
17. Cassileth PA, Begg CB, Bennett JM, et al: A randomized study of the efficacy of consolidation therapy in adult acute non-lymphocytic leukemia. Blood 63;843-847, 1984
18. Preisler HD, Raza A, Early A, et al: Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 5;722-730, 1987
19. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
20. Bolwell BJ, Cassileth PA, Gale RP: High-dose cytarabine: A review. Leukemia 2;253-260, 1988
21. Bow EJ, Kilpatrick MG, Scott BA, et al: Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high-dose cytarabine post-remission consolidation for myelosuppression, infectious morbidity and outcome. Cancer 74:52-60, 1994
22. Petti MC, Mandelli F, Avvisati G, et al: High-dose ARA-C (Hi DAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: A pilot multicentric study by the Italian Cooperative Group GIMEMA. Eur J Haematol 42:24-31, 1989
23. van Prooijen HC, Dekker AW, Punt K: The use of intermediate dose cytarabine arabinoside (ID ARA-C) in the treatment of acute non-lymphocytic leukemia in relapse. Br J Haematol 57:291-299, 1984
24. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-America-British Cooperative Group. Ann Intern Med 103:620-625, 1985
25. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
26. Bow EJ, Rayner E, Louie TJ: Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. Am J Med 84:847-854, 1988
27. Hughes NT, Armstrong D, Bodey GD, et al: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381-396, 1990
28. Brito-Babapulle F, Catovsky D, Galton DAG: Clinical and laboratory features of de-novo acute myeloid leukemia with tri-lineage dysplasia. Br J Haematol 66:445-450, 1987
29. Mitelman F (ed): ISCN (1991): Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature. Basel Switzerland, Karger, 1991
30. Arthur DC, Berger R, Golumb HM, et al: The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203-216, 1989
31. Swansbury GJ, Lawler SD, Alimena G, et al: Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 73:1-7, 1994
32. Bow EJ, Loewen R, Cheang MS, et al: Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 21:361-369, 1995
33. Schipper H, Clinch J, McMurray A, et al: Measurement of quality of life in cancer patients: The Functional Living Index - Cancer: Development and validation. J Clin Oncol 2:472-483, 1984
34. Kaplan ER, Meier R: Non-parametric estimation from incompatible observations. J Am Stat Assoc 53:457-481, 1958
35. Cox DR: Regression models and life tables. J R Stat Soc 34:187-202, 1972
36. Miller AB, Hoogstraten B, Staquet M, et al: Reporting of cancer treatment. Cancer 47:207-214, 1981
37. Estey E, Pierce H, Kantarjian H, et al: Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 11:59-63, 1993
38. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia. Blood 73:263-270, 1989
39. Bloomfield CD, Lawrence D, Arthur DC, et al: Cureative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:111a, 1994 (suppl 1, abstr 431)
40. Vogler RV, Velez-Garcia E, Weiner RS, et al: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 10:1103-1111, 1992
41. Bow EJ, Ronald AR: Antibacterial prophylaxis in neutropenic patients: Where do we go from here? Clin Infect Dis 17:333-337, 1993 (editorial)
42. Stalfelt AM: Quality of life of patients with acute myeloid leukaemia. Leuk Res 18:257-267, 1994